ReviewSeminars in nuclear medicine2025
Total Body PET/CT: Future Aspects.
Review in Seminars in nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Large axial field of view PET/CT - Not just a longer PET gantry.Zeitschrift fur medizinische Physik · 2026Review
- Monte Carlo-based scatter correction for the plastic-based modular PET scanner J-PET.Physics in medicine and biology · 2026Article
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
- Time-of-Flight Requirements to Mitigate Blurring Induced by Annihilation Photon Acollinearity.IEEE transactions on radiation and plasma medical sciences · 2026Article
- LAFOV PET as an enabling platform for pharmacokinetics-informed digital twins.Frontiers in medicine · 2026Article
- The Rise of Total-Body PET/CT: Advancing Molecular Imaging Toward Early Cancer Detection and Potential Future Application in Prevention Healthcare.Journal of clinical medicine · 2025Review
- Staging lung cancer: total-body PET/CT or whole-body PET/CT?EJNMMI research · 2025Article
- A scoping review on potential of novel developments in fever of unknown origin and inflammation of unknown origin: long-axial-field-of-view positron emission tomography/computed tomography and novel radiotracers.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Total-body (TB) positron emission tomography (PET) scanners are classified by their axial field of view (FOV). Long axial field of view (LAFOV) PET scanners can capture images from eyes to thighs in a one-bed position, covering all major organs with an axial FOV of about 100 cm. However, they often miss essential areas like distal lower extremities, limiting their use beyond oncology.TB-PET is reserved for scanners with a FOV of 180 cm or longer, allowing coverage of most of the body. LAFOV PET technology emerged about 40 years ago but gained traction recently due to advancements in data acquisition and cost. Early research highlighted its benefits, leading to the first FDA-cleared TB-PET/CT device in 2019 at UC Davis. Since then, various LAFOV scanners with enhanced capabilities have been developed, improving image quality, reducing acquisition times, and allowing for dynamic imaging. The uEXPLORER, the first LAFOV scanner, has a 194 cm active PET AFOV, far exceeding traditional scanners. The Panorama GS and others have followed suit in optimizing FOVs. Despite slow adoption due to the COVID pandemic and costs, over 50 LAFOV scanners are now in use globally. This review explores the future of LAFOV technology based on recent literature and experiences, covering its clinical applications, implications for radiation oncology, challenges in managing PET data, and expectations for technological advancements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.